High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.
CNBC’s Jim Cramer pushed viewers away from the usual semiconductor and hyperscaler chatter. Instead, he highlighted a group he says has quietly become the market’s leader. “There is a move in biotech that we have not talked about at all that is really extraordinary, and particularly since the change at the head of the FDA,” ... Jim Cramer Says Biotech is The Hottest Group in The Market Right Now
Amgen trades at $365.22 per share and has stayed right on track with the overall market, gaining 12% over the last six months. At the same time, the S&P 500 has returned 7.7%.
Amgen (AMGN) has moved into focus after initiating voluntary nationwide recalls of certain Corlanor and Sensipar tablet lots due to foreign substances and CGMP deviations, prompting investors to reassess drug quality and compliance risks. See our latest analysis for Amgen. Against this recall backdrop, Amgen’s recent momentum has stayed intact, with a 30 day share price return of 5.30% and a year to date share price return of 12.35%. The 1 year total shareholder return of 27.66% and 3 year...
In early June 2026, a federal judge granted Amgen a preliminary injunction blocking Colorado’s proposed 70% price cap on its rheumatoid arthritis drug Enbrel, while the company also initiated several voluntary Class II recalls of Corlanor and Sensipar batches in the United States over foreign substances and CGMP deviations. This mix of regulatory relief on Enbrel’s pricing and ongoing quality-related recalls raises important questions about how investors weigh pricing power against...
Near-term headwinds could sink the stock, but there is more to the story.
Amgen has initiated several product recalls in the US for Sensipar (cinacalcet) and Corlanor (ivabradine). The recalls involve multiple lots, dosage strengths, and large product quantities distributed nationwide. Regulators cited current good manufacturing practice (CGMP) deviations and contamination concerns affecting certain products. The pattern of recurring recalls extends beyond a single isolated lot or event. For investors following Amgen, ticker NasdaqGS:AMGN, the scale and...
On CNBC’s Mad Dash segment on Monday, July 6, 2026, Jim Cramer made one of his most bullish biotech calls in years, arguing that the sector could be entering a new wave of mergers and acquisitions as the regulatory environment becomes more favorable for dealmaking. “There is a move in biotech that we have not ... Jim Cramer Calls Biotech “The Hottest Group in the Market” as He Predicts “Deals Are Going to Be Flooding the Market”
Amgen (AMGN) closed the most recent trading day at $366.44, moving 2.06% from the previous trading session.
By Karen Roman VERAXA Biotech AG (Nasdaq: VRXA) said it expects BiTAC molecules to be the company’s main value drivers and to dominate its pipeline development in the upcoming years, hence receiving VERAXA’s main share of investments to have a first BiTAC-T cell engager candidate ready by early 2028. The company stated its half-year progress […] The post The Cancer Therapy Strategy VERAXA Is Betting the Company On appeared first on ExecEdge.
Amgen (AMGN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Here is how Allarity Therapeutics, Inc. (ALLR) and Amgen (AMGN) have performed compared to their sector so far this year.
US stocks are predicted to see a mixed start on Monday, with investors rotating back into technology shares after a softer-than-expected jobs report last week eased concerns that the Federal Reserve could raise interest rates again. Nasdaq futures were 1.1% higher ahead of the first trading...
8.39am: Airlines and pubs in good mood Shares in easyJet have flown almost 10% higher to 610p but are still well below the 690p potential offer price. Sector peer Jet2 is up 3.8% too, while long-haul peer IAG has risen 2.1%. The FTSE 100 and FTSE 250 are both on the front foot, up...
RHHBY announces positive phase III Krascendo 1 results for divarasib in KRAS G12C NSCLC, showing PFS and OS gains versus approved inhibitors.
The biggest names in tech, e-commerce, and digital transformation are in the Nasdaq 100 (^NDX), but only a few are leading the pack. Some companies in this index are proving their resilience and expanding their competitive advantages.
Shares of biotech company Amgen (NASDAQ:AMGN) jumped 3.1% in the afternoon session after the company received a favorable court ruling that blocked a first-of-its-kind state price cap on its blockbuster drug, Enbrel.
The Phase 3 trial compared Roche’s divarasib with treatments sold by Amgen and Bristol Myers in patients with non-small cell lung cancer.
Experimental drug, divarasib, showed meaningful improvements in both patients’ overall survival and the time they survived without the disease worsening.
Experimental drug, divarasib, showed meaningful improvements in both patients’ overall survival and the time they survived without the disease worsening.
July 1 (Reuters) - A federal judge on Wednesday blocked Colorado from capping the price of Amgen's blockbuster arthritis drug Enbrel, a first-of-its-kind move by a U. In granting a preliminary injunction, Chief Judge Daniel Domenico of the Denver federal court said Amgen would likely face significant and irreparable harm from charging lower prices, adding that it could affect the drugmaker's negotiations for future contracts with wholesalers and distributors.
AMGN stands out compared to Biogen given its broader product portfolio, pipeline depth and steadier growth outlook despite patent and competition risks.
This further weakens Amgen’s case for Tavneos’ continued use on the market as the drug comes under intense regulatory scrutiny.
Amgen Inc. (NASDAQ:AMGN) ranks among the top NASDAQ stocks for retirement. On June 16, Mizuho increased its price target for Amgen Inc. (NASDAQ:AMGN) to $303 from $295 while keeping a Neutral rating on the company’s shares, with the firm highlighting MariTide and olpasiran as crucial focal points for the company. Mizuho said that Novartis and […]
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended revoking Amgen’s Tavneos marketing authorization in the EU. The recommendation concerns Tavneos, a treatment for certain autoimmune conditions, and focuses on its continued approval in European markets. This regulatory step introduces fresh questions for investors following Amgen (NasdaqGS:AMGN) beyond earlier topics such as valuation and patent issues. For investors watching Amgen, this...
FDA and European regulators continue seeking Tavneos withdrawal as Amgen contests the proposed market action.
We use Google Analytics to count anonymous page views and understand which content gets read. No ads, no profiles. Decline keeps you on cookieless mode. Details.
